MCP-1 and soluble TWEAK levels are independently associated with coronary artery disease severity in patients with chronic kidney disease

Akdoğan, Mehmet Fatih; Azak, Alper; Denizli, Nazım; Huddam, Bülent; Koçak, Gülay; Gücün, Murat; Tatlısu, Mustafa Adem; Demi̇rci̇, Recep; Yılmaz, Bilal; Dikeç, Mehmet; Bakırtaş, Murat; Akdağ, İ̇brahim; Duranay, Murat

doi:10.3109/0886022x.2015.1065428

Cited by 13 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Senescence‐associated secretory phenotype can promote secondary senescence in healthy cells (Coppe, Desprez, Krtolica & Campisi, ), and senescent cells have been demonstrated to promote aging and age‐related disease (Baker et al., , ; Zhu et al., ). Circulating levels of MCP‐1 are increased in patients with renal disease (Akdogan et al., ), cognitive impairment and Alzheimer's disease (Bettcher et al., ), atherosclerosis and cardiovascular disease (Deo et al., ). Monocyte chemoattractant protein‐1 is considered to be a marker of “inflammaging,” defined as chronic sterile inflammation that is associated with numerous age‐related diseases (Franceschi & Campisi, ).…”

Section: Resultsmentioning

confidence: 99%

Circulating levels of monocyte chemoattractant protein‐1 as a potential measure of biological age in mice and frailty in humans

et al. 2017

View full text Add to dashboard Cite

SummaryA serum biomarker of biological versus chronological age would have significant impact on clinical care. It could be used to identify individuals at risk of early‐onset frailty or the multimorbidities associated with old age. It may also serve as a surrogate endpoint in clinical trials targeting mechanisms of aging. Here, we identified MCP‐1/CCL2, a chemokine responsible for recruiting monocytes, as a potential biomarker of biological age. Circulating monocyte chemoattractant protein‐1 (MCP‐1) levels increased in an age‐dependent manner in wild‐type (WT) mice. That age‐dependent increase was accelerated in Ercc1 −/Δ and Bubr1 H/H mouse models of progeria. Genetic and pharmacologic interventions that slow aging of Ercc1 −/Δ and WT mice lowered serum MCP‐1 levels significantly. Finally, in elderly humans with aortic stenosis, MCP‐1 levels were significantly higher in frail individuals compared to nonfrail. These data support the conclusion that MCP‐1 can be used as a measure of mammalian biological age that is responsive to interventions that extend healthy aging.

show abstract

Section: Resultsmentioning

confidence: 99%

Circulating levels of monocyte chemoattractant protein‐1 as a potential measure of biological age in mice and frailty in humans

et al. 2017

View full text Add to dashboard Cite

show abstract

“…[ 6 ] Abnormal expression of MCP-1 has been observed in various diseases, such as clear-cell renal cell carcinoma, cerebral ischemic stroke, coronary artery disease. [ 7 – 9 ] Hyperglycemia can enhance the production of MCP-1 in vascular endothelial cells and its abnormal expression may contribute to the complications related to angiogenesis and vascular functions among T2DM patients. [ 6 ] Recently, growing studies have indicated that the polymorphisms of MCP-1 –2518A/G may influence the production of MCP-1 .…”

Section: Introductionmentioning

confidence: 99%

The association between MCP-1, VEGF polymorphisms and their serum levels in patients with diabetic foot ulcer

Li¹

2018

Medicine

View full text Add to dashboard Cite

The purpose of the present study was to investigate distribution of monocyte chemoattractant protein-1 (MCP-1) –2518A/G and vascular endothelial growth factor (VEGF) –634G/C polymorphisms in type 2 diabetes melitus patients (T2DM) presenting diabetic foot ulcer (DFU). Additionally, we evaluated the effects of these 2 polymorphisms on serum levels of MCP-1 and VEGF in the study population.Patients diagnosed with T2DM without or with DFU were recruited in the study. The distribution of MCP-1 –2518A/G and VEGF –634G/C polymorphisms was investigated by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Enzyme-linked immunosorbent assay (ELISA) was applied to detect the protein levels of MCP-1 and VEGF. The comparisons of protein levels in DFU patients were performed by student t test according to their genotypes.The frequencies of GG genotype and G allele of MCP-1 –2518A/G was increased in DFU patients, compared with T2DM patients (odds ratio [OR] = 2.60, 95% confidence interval [CI] = 1.23–5.50, P = .011 and OR = 1.72, 95% CI = 1.18–2.50, P = .005, respectively). Moreover, the increased frequency of GG was significantly associated with up-regulated MCP-1 level in DFU patients (P < .001). Analysis for VEGF –634G/C polymorphisms indicated that the prevalence of CC genotype and C allele of the polymorphisms was decreased in DFU patients, compared with T2DM patients (OR = 0.36, 95% CI = 0.17–0.77, P = .008 and OR = 0.63, 95% CI = 0.43–0.91, P = .015, respectively). DFU patients carrying CC genotype had a higher level of VEGF than those with other genotypes (P = .007).MCP-1 –2518A/G and VEGF –634G/C polymorphisms may involve in occurrence and progress of DFU through regulating transcription activity of the genes.

show abstract

“…Previous studies have indicated that the levels of MCP-1 in blood are related with the severity of coronary artery disease in patients with chronic kidney disease [ 20 ] and with the disease activity of rheumatoid arthritis [ 21 ]. MCP-1 is known as a prognostic factor for lung, cervical, and ovarian cancers [ 22 , 23 , 24 ].…”

Section: Introductionmentioning

confidence: 99%

Plasma Monocyte Chemoattractant Protein-1 Level as a Predictor of the Severity of Community-Acquired Pneumonia

Yong

Chang

Chien

et al. 2016

IJMS

View full text Add to dashboard Cite

Monocyte chemoattractant protein (MCP)-1 increases in the serum of immunocompetent patients with community-acquired pneumonia (CAP). However, the correlation between the circulating level of MCP-1 and severity of CAP remains unclear. This study investigated differential changes in the plasma MCP-1 levels of patients with CAP before and after an antibiotic treatment and further analyzes the association between the CAP severity and MCP-1 levels. We measured the plasma MCP-1 levels of 137 patients with CAP and 74 healthy controls by using a commercial enzyme-linked immunosorbent assay. Upon initial hospitalization, Acute Physiology and Chronic Health Evaluation II (APACHE II); confusion, urea level, respiratory rate, blood pressure, and age of >64 years (CURB-65); and pneumonia severity index (PSI) scores were determined for assessing the CAP severity in these patients. The antibiotic treatment reduced the number of white blood cells (WBCs) and neutrophils as well as the level of C-reactive protein (CRP) and MCP-1. The plasma MCP-1 level, but not the CRP level or WBC count, correlated with the CAP severity according to the PSI (r = 0.509, p < 0.001), CURB-65 (r = 0.468, p < 0.001), and APACHE II (r = 0.360, p < 0.001) scores. We concluded that MCP-1 levels act in the development of CAP and are involved in the severity of CAP.

show abstract

MCP-1 and soluble TWEAK levels are independently associated with coronary artery disease severity in patients with chronic kidney disease

Abstract: Our findings support a relationship between sTWEAK and MCP-1 levels and CAD in CKD stages 2-3 patients.

Cited by 13 publications

References 24 publications

Circulating levels of monocyte chemoattractant protein‐1 as a potential measure of biological age in mice and frailty in humans

Circulating levels of monocyte chemoattractant protein‐1 as a potential measure of biological age in mice and frailty in humans

The association between MCP-1, VEGF polymorphisms and their serum levels in patients with diabetic foot ulcer

Plasma Monocyte Chemoattractant Protein-1 Level as a Predictor of the Severity of Community-Acquired Pneumonia

Contact Info

Product

Resources

About